In December of 2022, Kite and Arcellx entered an agreement to develop and commercialise Arcellx’s multiple myeloma product candidate CART-ddBCMA.
The candidate is currently in Phase 2 clinical development and is a cell therapy product comprising of genetically modified autologous T cells. The collaboration brings together Arcellx’s promising CART-ddBCMA therapy with Kite’s expertise and leadership in cell therapy. Arcellx will receive an upfront cash payment of $225 million and $100 million of equity investment. In addition, Arcellx is eligible to receive clinical, regulatory, and commercial milestone payments totaling $1.47 billion as per their 5/23 10-Q report. Costs for development, clinical trials, and commercialisation of CART-ddBCMA will be shared between the companies and U.S. profits from the product will be split 50/50.
